Results 171 to 180 of about 13,388,827 (299)

Insulin Efsitora Demonstrates Similar Efficacy and Safety Profiles to Insulin Icodec in Insulin‐Experienced Individuals With Type 2 Diabetes Mellitus: Matching‐Adjusted Indirect Comparisons of QWINT‐3 Versus ONWARDS 2, and QWINT‐4 Versus ONWARDS 4

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To conduct indirect treatment comparisons (ITCs) of insulin efsitora alfa (efsitora) versus insulin icodec (icodec) in insulin‐experienced individuals with Type 2 Diabetes Mellitus. Methods Efficacy, safety and patient reported outcomes were compared via matching‐adjusted ITCs using results from randomised controlled trials: QWINT‐3 ...
Harpreet S. Bajaj, Marvin Fischer, Michael B. Davidson, Abdul M. Tarafder, Christopher J. Michaels, Rachel H. Tao, Alex Pashley, Jess Amis, Josefine Redig   +8 more
wiley   +1 more source

Endogenous GIP signaling is indispensable for DPP-4 inhibitor-mediated metabolic control in mice. [PDF]

J Diabetes Investig
Kubota-Okamoto S, Kubota S, Tsuchida H, Liu Y, Banno S, Imaizumi T, Fujisawa T, Takahashi Y, Kato T, Horikawa Y, Iizuka K, Murakami T, Fujiwara Y, Kuwata H, Yamazaki Y, Seino Y, Tsunekawa S, Yabe D.   +17 more
europepmc   +1 more source

Exploratory Analysis of Type 2 Diabetes Mellitus Metabolic Phenotypes and Their Association With Vitamin D Status in Primary Care Patients

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This study aimed to perform an exploratory characterisation of metabolic phenotypes in primary care patients with type 2 diabetes mellitus (T2DM), using a predefined approach and examine their association with vitamin D status. Materials and Methods This cross‐sectional study included 178 participants randomly selected in Sergipe, Brazil.
Liliane Viana Pires, Matheus Menezes‐Santos, Andréa Costa Goes, Heitor Siqueira Ribeiro, Luana Ferreira Alves, Beatriz Cruz dos Santos, Jéssyca Teles Barreto, Roberta Cristina Vieira Meneses, Ana Mara de Oliveira e Silva, Ana Hermínia Andrade e Silva, Sadraque Eneas de Figueiredo Lucena   +10 more
wiley   +1 more source

Gingival-Dominant Presentation of DPP-4 Inhibitor-Associated Bullous Pemphigoid: A Case Report. [PDF]

Cureus
Fujii Y, Kataoka T, Togashi C, Ishikawa M, Kawase-Koga Y.   +4 more
europepmc   +1 more source

Does DPP-4 inhibitor treatment affect the clinical outcomes of COVID-19 in type 2 diabetes mellitus patients? [PDF]

North Clin Istanb, 2022
Erol RS, Sen EC, Ozturk FY, Sarac Z, Kokoglu GL, Canat MM, Yildiz D, Aytekin YE, Sevgi DY, Altuntas Y.   +9 more
europepmc   +1 more source

The SGLT2i Treatment Gap in UK Primary Care: A Cross‐Sectional RWE Study of Prescribing in Clinical Practice

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) improve cardiovascular and renal outcomes in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD) and chronic heart failure (CHF). Despite clinical guideline recommendations, SGLT2i uptake in UK primary care remains suboptimal and information on utilisation is limited.
Chelsea Stefanska, Ryan Chung, Salman Ramjaun, Danyao Jin, Ciara Doherty, Kieran McCafferty, Samuel Seidu   +6 more
wiley   +1 more source

Preclinical pharmacological profiles of cofrogliptin, a novel and bi-weekly DPP-4 inhibitor. [PDF]

Front Pharmacol
Gou X, Dou C, Tang P, Zheng X, Zhang C, Wang J, Meng Q, Wang J.   +7 more
europepmc   +1 more source

Lower Risk of Incident Dementia with SGLT2 Inhibitor Versus DPP-4 Inhibitor Initiation in Patients with Type 2 Diabetes and Prior Traumatic Brain Injury: A Retrospective Cohort Study. [PDF]

Drug Des Devel Ther
Hung KC, Weng HL, Chen IW.
europepmc   +1 more source

Cost and clinical impact of a nonmedical DPP-4 inhibitor switch in patients with diabetes. [PDF]

J Manag Care Spec Pharm, 2021
Kheloussi S, Johns A, Parente V, McLay W, Gionfriddo MR.   +4 more
europepmc   +1 more source

Real‐World Cost and Utilisation Burden of Diagnosed Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes in the United States: A Retrospective Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This study quantified the real‐world healthcare costs and utilisation associated with diagnosed metabolic dysfunction‐associated steatotic liver disease (MASLD) among adults with Type 2 diabetes (T2D). Methods We conducted a retrospective cohort study using IQVIA PharMetrics Plus Closed Health Plan data from January 2016 to June 2025 ...
Tien Hoang Tran, Hyung‐Seok Kim, Rozalina G. McCoy, Zafar Zafari   +3 more
wiley   +1 more source